[go: up one dir, main page]

RU2005140516A - Применение ингибитора тирозинкиназы для лечения диабета - Google Patents

Применение ингибитора тирозинкиназы для лечения диабета Download PDF

Info

Publication number
RU2005140516A
RU2005140516A RU2005140516/15A RU2005140516A RU2005140516A RU 2005140516 A RU2005140516 A RU 2005140516A RU 2005140516/15 A RU2005140516/15 A RU 2005140516/15A RU 2005140516 A RU2005140516 A RU 2005140516A RU 2005140516 A RU2005140516 A RU 2005140516A
Authority
RU
Russia
Prior art keywords
diabetes
methylpiperazin
ylamino
benzamide
pyrimidin
Prior art date
Application number
RU2005140516/15A
Other languages
English (en)
Other versions
RU2365373C2 (ru
Inventor
Пер Роберт ХЭГЕРКВИСТ (SE)
Пер Роберт ХЭГЕРКВИСТ
Нильс Ричард УЭЛШ (SE)
Нильс Ричард Уэлш
Original Assignee
Хэгерквист Роберт Пер (Se)
Хэгерквист Роберт Пер
Нильс Ричард УЭЛШ (SE)
Нильс Ричард Уэлш
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0312086A external-priority patent/GB0312086D0/en
Priority claimed from GB0402682A external-priority patent/GB0402682D0/en
Application filed by Хэгерквист Роберт Пер (Se), Хэгерквист Роберт Пер, Нильс Ричард УЭЛШ (SE), Нильс Ричард Уэлш filed Critical Хэгерквист Роберт Пер (Se)
Publication of RU2005140516A publication Critical patent/RU2005140516A/ru
Application granted granted Critical
Publication of RU2365373C2 publication Critical patent/RU2365373C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Claims (8)

1. Применение 4-(4-метилпиперазин-1-илметил)-N-[4-метил-3-(4-пиридин-3-ил)пиримидин-2-иламино)фенил]-бензамида или его фармацевтически приемлемой соли для получения лекарственного средства для лечения или предупреждения диабета.
2. Применение 4-(4-метилпиперазин-1-илметил)-N-[4-метил-3-(4-пиридин-3-ил)пиримидин-2-иламино)фенил]-бензамида или его фармацевтически приемлемой соли для получения лекарственного средства для лечения диабета.
3. Применение 4-(4-метилпиперазин-1-илметил)-N-[4-метил-3-(4-пиридин-3-ил)пиримидин-2-иламино)фенил]-бензамида или его фармацевтически приемлемой соли для получения лекарственного средства для предупреждения диабета.
4. Применение по одному из пп.1-3, в котором диабетом является диабет I типа.
5. Применение по одному из пп.1-3, в котором диабетом является диабет II типа.
6. Применение по п.4, в котором 4-(4-метилпиперазин-1-илметил)-N-[4-метил-3-(4-пиридин-3-ил)пиримидин-2-иламино)фенил]-бензамид находится в форме монометансульфонатной соли.
7. Применение по п.5, в котором 4-(4-метилпиперазин-1-илметил)-N-[4-метил-3-(4-пиридин-3-ил)пиримидин-2-иламино)фенил]-бензамид находится в форме монометансульфонатной соли.
8. Упаковка лекарственного средства, содержащая 4-(4-метилпиперазин-1-илметил)-N-[4-метил-3-(4-пиридин-3-ил)пиримидин-2-иламино)фенил]-бензамид или его фармацевтически приемлемую соль, вместе с отпечатанными инструкциями, для введения пациентам, болеющим диабетом, например, диабетом I типа, диабетом II типа.
RU2005140516/15A 2003-05-27 2004-05-26 Применение ингибитора тирозинкиназы для лечения диабета RU2365373C2 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0312086.2 2003-05-27
GB0312086A GB0312086D0 (en) 2003-05-27 2003-05-27 Organic compounds
GB0402682.9 2004-02-06
GB0402682A GB0402682D0 (en) 2004-02-06 2004-02-06 Organic compounds

Publications (2)

Publication Number Publication Date
RU2005140516A true RU2005140516A (ru) 2007-07-10
RU2365373C2 RU2365373C2 (ru) 2009-08-27

Family

ID=33492240

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2005140516/15A RU2365373C2 (ru) 2003-05-27 2004-05-26 Применение ингибитора тирозинкиназы для лечения диабета

Country Status (20)

Country Link
US (1) US7875616B2 (ru)
EP (1) EP1631291B1 (ru)
JP (1) JP4776537B2 (ru)
KR (1) KR101102229B1 (ru)
AT (1) ATE439133T1 (ru)
BR (1) BRPI0410704A (ru)
CA (1) CA2526594C (ru)
DE (1) DE602004022540D1 (ru)
DK (1) DK1631291T3 (ru)
ES (1) ES2331800T3 (ru)
IL (1) IL171927A (ru)
IS (1) IS2712B (ru)
MA (1) MA27812A1 (ru)
MX (1) MXPA05012739A (ru)
NO (1) NO331715B1 (ru)
NZ (1) NZ543709A (ru)
PL (1) PL1631291T3 (ru)
PT (1) PT1631291E (ru)
RU (1) RU2365373C2 (ru)
WO (1) WO2004105763A2 (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1653934B1 (en) * 2003-08-15 2008-05-14 AB Science Use of c-kit inhibitors for treating type ii diabetes
US20060094682A1 (en) * 2004-10-29 2006-05-04 Odyssey Thera, Inc. Kinase inhibitors for the treatment of diabetes and obesity
CN101484427A (zh) * 2006-06-30 2009-07-15 协和发酵麒麟株式会社 Abl激酶抑制剂
CN103826634A (zh) * 2011-09-15 2014-05-28 诺华股份有限公司 4-氨基-5-氟-3-[6-(4-甲基哌嗪-1-基)-1h-苯并咪唑-2-基]-1h-喹啉-2-酮在治疗中度肝损伤患者癌症中的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW225528B (ru) * 1992-04-03 1994-06-21 Ciba Geigy Ag
EP1714652A3 (en) * 1993-09-15 2007-01-17 Sankyo Company, Limited Use of thiazolidinediones to prevent or delay onset of niddm
EP0773313B1 (de) * 1995-10-11 2000-08-09 ARTEVA TECHNOLOGIES S.à.r.l. Schwerentflammbare Sicherheitsgurte enthaltend phosphor-modifizierte Polyesterfasern
CO4940418A1 (es) * 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
GB9716557D0 (en) * 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
EP1033364B1 (en) * 1999-03-01 2005-02-23 Pfizer Products Inc. Cyano containing oxamic acids and derivatives as thyroid receptor ligands
JP2004500380A (ja) * 2000-02-15 2004-01-08 テバ　ファーマシューティカル　インダストリーズ　リミティド レフルノミドの合成方法
US7087608B2 (en) * 2000-03-03 2006-08-08 Robert Charles Atkins Use of PDGF receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy
TWI270545B (en) * 2000-05-24 2007-01-11 Sugen Inc Mannich base prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
WO2002055517A2 (en) * 2000-12-20 2002-07-18 Jingrong Cui 4-(hetero)aryl substituted indolinones
WO2003020698A2 (en) 2001-09-06 2003-03-13 Prochon Biotech Ltd. Protein tyrosine kinase inhibitors
AUPS243002A0 (en) 2002-05-20 2002-06-13 Baker Medical Research Institute Therapeutic target and uses thereof
DE10235227A1 (de) * 2002-08-01 2004-02-19 Johann Berger Verfahren zur Herstellung eines gewebten Gurtbandes
WO2004015082A2 (en) 2002-08-09 2004-02-19 Theravance, Inc. Oncokinase fusion polypeptides associated with hyperproliferative and related disorders, nucleic acids encoding the same and methods for detecting and identifying the same
AU2003295604A1 (en) 2002-11-13 2004-06-03 Genpath Pharmaceuticals, Incorporated Gpc15: methods and compositions for treating cancer
DE10255360A1 (de) * 2002-11-27 2004-06-17 Johann Berger Verfahren zur Herstellung eines gewebten Gurtbandes

Also Published As

Publication number Publication date
KR20060021865A (ko) 2006-03-08
PT1631291E (pt) 2009-10-28
RU2365373C2 (ru) 2009-08-27
KR101102229B1 (ko) 2012-01-05
WO2004105763A3 (en) 2005-06-02
EP1631291A2 (en) 2006-03-08
JP4776537B2 (ja) 2011-09-21
IL171927A (en) 2011-10-31
DE602004022540D1 (de) 2009-09-24
HK1087638A1 (en) 2006-10-20
NO331715B1 (no) 2012-03-05
ATE439133T1 (de) 2009-08-15
BRPI0410704A (pt) 2006-06-13
NZ543709A (en) 2009-04-30
NO20056188L (no) 2005-12-23
MXPA05012739A (es) 2006-05-17
CA2526594C (en) 2011-11-08
EP1631291B1 (en) 2009-08-12
PL1631291T3 (pl) 2010-04-30
CA2526594A1 (en) 2004-12-09
AU2004243491A1 (en) 2004-12-09
IL171927A0 (en) 2006-04-10
JP2006528225A (ja) 2006-12-14
DK1631291T3 (da) 2009-11-02
US7875616B2 (en) 2011-01-25
ES2331800T3 (es) 2010-01-15
IS2712B (is) 2011-01-15
IS8139A (is) 2005-11-22
US20070072932A1 (en) 2007-03-29
WO2004105763A2 (en) 2004-12-09
MA27812A1 (fr) 2006-03-01

Similar Documents

Publication Publication Date Title
RU2458920C2 (ru) Новые соединения
JP2004512328A5 (ru)
BRPI0114870B8 (pt) uso de 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il)pirimidin-2-amino)fenil]-benzamida para a fabricação de composições farmacêuticas para tratamento de tumores estromais gastrointestinais
JP2008110984A5 (ru)
RS52256B (en) THERAPEUTIC USES OF COMPOUNDS WITH COMBINED SERT, 5-HT3 AND 5-HT1A ACTIVITIES
PT998473E (pt) Modificacao da forma de cristal de um derivado de n-fenil-2-pirimidinoamina processos para a sua preparacao e sua utilizacao
CY1106430T1 (el) Φαρμακα για εισπνοη που πepιλαμβανουν βηταμιμητικα και αντιχολινepγικο
CY1113566T1 (el) Καρβαμοϋλο-κυκλοεξανια για τη θεραπευτικη αγωγη της οξειας μανιας
EA201100916A1 (ru) Комбинация инсулина с триазиновыми производными и их применение для лечения диабета
RU2007147957A (ru) Комбинация производных пиримидиламинобензамида и иматиниба для лечения или профилактики пролиферативных заболеваний
RU2005140516A (ru) Применение ингибитора тирозинкиназы для лечения диабета
IL162983A (en) Use of imatinib for the manufacture of pharmaceutical compositions for the treatment of rheumatoid arthritis
CA2504665A1 (en) Combination of a nitrogen mustard analogue and imatinib for the treatment of chronic lymphocytic leukemia
RU2008103549A (ru) Применение активаторов растворимой гуанилат-циклазы для лечения нарушений кровоснабжения
PE20040534A1 (es) Medicamentos que comprenden tiofenos sustituidos y procedimientos para su preparacion
RU2004112422A (ru) Роувастатин в преддеменционных состояниях
Rao et al. Comparison between epidural ropivacaine versus ropivacaine with clonidine in patients undergoing abdominal hysterectomy: A randomized study
PE20030236A1 (es) Derivados de bencimidazol 1-aril-2-n,s- u o-sustituidos, obtencion de medicamentos y preparados farmaceuticos que contienen estos derivados
UA89617C2 (en) Succinate and malonate salt of trans 4-(1r,3s)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine and use thereof as a medicament
SE0102886D0 (sv) New formulation
JP2005508846A5 (ru)
TH22562B (th) เกลือเมซีเลทไดไฮเดรทของ 5-(2-(4-(1,2-เบนไซโซไทอะโซล-3-อิล)-1-พิเพอราซินิล)เอทิล)-6-คลอโร-1,3-ไดไฮโดร-2h-อินโดล-2-โอน
DE60305460D1 (de) Verwendung von 4-(4-methylpiperazin-1-ylmethyl)-n 4-methyl-3-(4-pyridin-3-yl) pyrimidin-2-ylamino) phenyl benzamid zur behandlung von seminomen

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20090527

NF4A Reinstatement of patent

Effective date: 20110927

MM4A The patent is invalid due to non-payment of fees

Effective date: 20150527